Investigational drug · Phase 3
Arlocabtagene Autoleucel
Also called: BMS-986393, GPRC5D CAR T cells
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Multiple Myeloma, Relapsed or Refractory Multiple Myeloma (RRMM).
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "Arlocabtagene Autoleucel"
First trial start
2024
Mar 21, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Arlocabtagene Autoleucel", any sponsor or status.
Conditions studied
As listed on its trial records.
- Multiple Myeloma
- Relapsed or Refractory Multiple Myeloma (RRMM)
Approved drugs for the same conditions: Multiple myeloma · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "Arlocabtagene Autoleucel" as an intervention, largest first.
- A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)Pivotal-lookingRecruiting
Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyBristol Myers Squibb (BMY)
NCT06615479 · 440 participants (planned) · Start Mar 12, 2025 · Primary completion Dec 30, 2027
Drug: BMS-986393; Cyclophosphamide and 5 more · For: Relapsed or Refractory Multiple Myeloma (RRMM)
Sites: Birmingham, Alabama; Los Angeles, California; Orange, California · 141 sites in all
Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyBristol Myers Squibb (BMY)
NCT06297226 · 230 participants (planned) · Start Mar 21, 2024 · Primary completion Jul 31, 2026
Drug: Arlocabtagene Autoleucel · For: Multiple Myeloma
Sites: Birmingham, Alabama; Gilbert, Arizona; Little Rock, Arkansas · 52 sites in all
Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyBristol Myers Squibb (BMY)
NCT06121843 · 187 participants (planned) · Start Feb 22, 2024 · Primary completion Aug 1, 2028
Drug: BMS-986393; Alnuctamab and 4 more · For: Multiple Myeloma
Sites: Birmingham, Alabama; Phoenix, Arizona; Duarte, California · 19 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Arlocabtagene autoleucel: a GPRC5D-targeted CAR T-cell therapy for heavily pretreated relapsed/refractory multiple myeloma.
Bal S, Htut M, Nadeem O, et al. · Blood 2026
- GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review.
Rodriguez-Otero P, van de Donk NWCJ, Pillarisetti K, et al. · Blood Cancer J 2024
Also in development for Multiple Myeloma
- EtentamigABBV-383, TNB-383BPhase 38 trials
AbbVie · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma, Amyloid Light Chain (AL) Amyloidosis
- BMS-986348CC-92480, mezigdomidePhase 37 trials
Bristol Myers Squibb · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma
- GR1803Velinotamig specified specified days., CLN-803Phase 37 trials
Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Multiple Myeloma, Immune Thrombocytopenia (ITP), Warm Autoimmune Hemolytic Anemia (WAIHA)
- JNJ-79635322Ramantamig, BCMAxGPRC5DxCD3Phase 37 trials
Johnson & Johnson (Janssen) · Multiple Myeloma
- Cilta-celJNJ-68284528Phase 36 trials
Johnson & Johnson (Janssen) · Multiple Myeloma
- Anitocabtagene AutoleucelCART-ddBCMAPhase 34 trials
Gilead Sciences · Multiple Myeloma, Newly Diagnosed Multiple Myeloma
- CevostamabRO7187797Phase 34 trials
Roche (Genentech) · Multiple Myeloma
- IBI3003Phase 34 trials
Innovent Biologics (Suzhou) Co. Ltd. · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Bristol Myers Squibb.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.